BR112019011350A2 - combination therapy - Google Patents

combination therapy

Info

Publication number
BR112019011350A2
BR112019011350A2 BR112019011350A BR112019011350A BR112019011350A2 BR 112019011350 A2 BR112019011350 A2 BR 112019011350A2 BR 112019011350 A BR112019011350 A BR 112019011350A BR 112019011350 A BR112019011350 A BR 112019011350A BR 112019011350 A2 BR112019011350 A2 BR 112019011350A2
Authority
BR
Brazil
Prior art keywords
immunomodulatory agent
type
antibody
antigen
present
Prior art date
Application number
BR112019011350A
Other languages
Portuguese (pt)
Inventor
Sherk Christian
Barbash Olena
Korenchuk Susan
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112019011350A2 publication Critical patent/BR112019011350A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se a uma combinação de um inibidor da proteína arginina metiltransferase tipo ii (prmt tipo ii) e agente imunomodulador, em que o agente imunomodulador é um anticorpo anti-ox40 ou um fragmento de ligação ao antígeno do mesmo. a presente invenção também fornece métodos para tratar câncer em um humano em necessidade de tratamento, compreendendo administrar ao ser humano uma combinação de um inibidor de prmt tipo ii e um agente imunomodulador, em que o agente imunomodulador é um anticorpo anti-ox40 ou um fragmento de ligação ao antígeno do mesmo, juntamente com ao menos um de: um carreador farmaceuticamente aceitável e um diluente farmaceuticamente aceitável, tratando assim o câncer no ser humano. a presente invenção fornece ainda uma composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz de um inibidor de prmt tipo ii e uma segunda composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz de um agente imunomodulador, em que o agente imunomodulador é um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo.The present invention relates to a combination of an arginine methyltransferase type ii protein inhibitor (prmt type ii) and immunomodulatory agent, wherein the immunomodulatory agent is an anti-ox40 antibody or antigen binding fragment thereof. The present invention also provides methods for treating cancer in a human in need of treatment, comprising administering to the human a combination of a type II prmt inhibitor and an immunomodulatory agent, wherein the immunomodulatory agent is an anti-ox40 antibody or fragment. antigen-binding agent thereof, together with at least one of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent, thereby treating cancer in humans. The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a type II prmt inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of an immunomodulatory agent, wherein the immunomodulatory agent is an anti-ox40 antibody or binding fragment. to its antigen.

BR112019011350A 2016-12-01 2017-11-30 combination therapy BR112019011350A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428764P 2016-12-01 2016-12-01
US201662433363P 2016-12-13 2016-12-13
PCT/IB2017/057549 WO2018100535A1 (en) 2016-12-01 2017-11-30 Combination therapy

Publications (1)

Publication Number Publication Date
BR112019011350A2 true BR112019011350A2 (en) 2019-10-22

Family

ID=60782286

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019011350A BR112019011350A2 (en) 2016-12-01 2017-11-30 combination therapy

Country Status (8)

Country Link
EP (1) EP3548068A1 (en)
JP (1) JP2020511407A (en)
KR (1) KR20190090823A (en)
CN (1) CN110234342A (en)
AU (1) AU2017369994A1 (en)
BR (1) BR112019011350A2 (en)
CA (1) CA3045243A1 (en)
WO (1) WO2018100535A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
CN110950841A (en) * 2019-11-22 2020-04-03 济南大学 Synthesis and application of novel triazole compounds
WO2021225963A2 (en) * 2020-05-04 2021-11-11 Sanford Burnham Prebys Medical Discovery Institute Methods and compositions for induction of antitumor immunity
US20230190707A1 (en) * 2020-05-15 2023-06-22 Fred Hutchinson Cancer Center Compositions and methods for enhancing cancer immunotherapy
CN113908283A (en) * 2021-09-30 2022-01-11 上海交通大学医学院附属新华医院 PRMT5 inhibitor and application thereof in combination with PD-L1 antibody blocking agent in treatment of lung cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (en) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド CTLA-4 binding peptides for immunotherapy
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
CZ303703B6 (en) 1998-12-23 2013-03-20 Pfizer Inc. Monoclonal antibody or fragment-binding antigen thereof, pharmaceutical composition in which the antibody or fragment is comprised, a cell line producing the antibody or fragment, process for preparing the antibody, isolated nucleic acid encoding hea
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Human monoclonal antibodies to CTLA-4
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (en) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Antibodies to CTLA4 (CD152), conjugates containing the same, and uses thereof
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc Agents that modulate immune cell activation and methods of use thereof
CA2471392A1 (en) 2001-12-22 2003-08-21 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
EP1525223B1 (en) 2002-06-13 2007-11-21 Crucell Holland B.V. Ox40 (=cd134) receptor agonists and therapeutic use
DE10161767T1 (en) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotentiating compositions containing an anti-PD-L1 antibody
MXPA05004022A (en) 2002-10-17 2005-10-05 Genmab As Human monoclonal antibodies against cd20.
ATE514713T1 (en) 2002-12-23 2011-07-15 Wyeth Llc ANTIBODIES TO PD-1 AND THEIR USE
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
WO2006063067A2 (en) 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
WO2007084559A2 (en) 2006-01-13 2007-07-26 Board Of Regents, The University Of Texas System Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
JP5761997B2 (en) 2007-12-14 2015-08-12 ブリストル−マイヤーズ・スクイブ・カンパニー Binding molecule for human OX40 receptor
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CN102203125A (en) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1 antagonists and methods of use thereof
JP5794917B2 (en) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ PD-1-specific antibodies and uses thereof
EP2342229A1 (en) 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
CN108997498A (en) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 Anti- PD-L1 antibody and they be used to enhance the purposes of T cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
DK3279215T3 (en) 2009-11-24 2020-04-27 Medimmune Ltd TARGETED BINDING AGENTS B7-H1
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
ES2630328T3 (en) 2010-08-23 2017-08-21 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and procedures for their use
PE20190262A1 (en) 2011-08-01 2019-02-25 Genentech Inc METHODS FOR TREATING CANCER BY USE OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
CA2845810C (en) 2011-08-23 2017-03-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
SI2785375T1 (en) 2011-11-28 2020-11-30 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
SG11201407190TA (en) * 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN104994873B (en) 2012-10-04 2017-12-22 达纳－法伯癌症研究所公司 The anti-PD L1 antibody of human monoclonal and application method
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2935242A2 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Methods of inhibiting prmt5
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CA2894126A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9604930B2 (en) * 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US20180271891A1 (en) * 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer

Also Published As

Publication number Publication date
WO2018100535A1 (en) 2018-06-07
AU2017369994A1 (en) 2019-06-13
EP3548068A1 (en) 2019-10-09
JP2020511407A (en) 2020-04-16
KR20190090823A (en) 2019-08-02
CA3045243A1 (en) 2018-06-07
CN110234342A (en) 2019-09-13

Similar Documents

Publication Publication Date Title
BR112019011350A2 (en) combination therapy
CY1124791T1 (en) CD73-SPECIFIC BINDING MOLECULES AND USES THEREOF
BR112018075198A2 (en) method for treating cancer or a pathogen-associated disease, pharmaceutical composition, and kit
BR112018069732A2 (en) methods for preventing, treating, reversing and / or delaying angiogenesis in a mammalian subject, for treating a subject suffering from ocular angiogenic disease or condition and for inhibiting tumor angiogenesis
AR104812A1 (en) THERAPEUTIC COMBINATIONS AND METHODS TO TREAT NEOPLASIAS
UA118453C2 (en) Modulation of tumor immunity
BR112012018951B8 (en) monoclonal antibody, pharmaceutical composition, pharmaceutical combination, use of an antibody, use of a pharmaceutical composition and use of a pharmaceutical combination
BR112020016331A8 (en) METHODS TO TREAT CANCER WITH ANTI-PD-1 ANTIBODIES
BR112018000212A2 (en) combined use of anti pd-1 and anti m-csf antibodies in cancer treatment
BR112018068512A2 (en) methods for treating er +, her2-, hrg + breast cancer using combination therapies comprising an anti-erbb3 antibody
BR112012018947B8 (en) monoclonal anti-caprin-1 antibody, pharmaceutical composition, pharmaceutical combination and uses of a pharmaceutical composition, an antibody and a pharmaceutical combination
BR112020015915A8 (en) USES OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA4 ANTIBODY OR ANTIGEN-BINDING FRAGMENTS THEREOF, AS WELL AS A KIT FOR TREATMENT OF A PATIENT WITH CANCER
BR112021015036A2 (en) Cancer treatment with ror1 antibody immunoconjugates
BR112019022280A2 (en) her2 positive cancer treatment
BR112017023517A2 (en) anti-cd20 antibody for cancer treatment, pharmaceutical composition, method of treating a cancer patient and use of an anti-cd20 antibody
BR112016008010A2 (en) use of semaphorin-4d binding molecules for atherosclerosis treatment
BR112021017350A2 (en) Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
EA201891853A1 (en) METHODS OF TREATMENT OR PREVENTION OF ATHEROSCLEROSIS BY INTRODUCING ANGPTL3 INHIBITOR
BR112016027043A8 (en) combination, pharmaceutical composition comprising glucocorticoid and edo-s101, kit and use in cancer treatment
BR112017007817A2 (en) cancer treatment with immune boosters
BR112018002436A2 (en) combination treatment of methods uses of these
BR112019023909A2 (en) method for treating a patient with ovarian cancer, peritoneal cancer or fallopian tube cancer.
BR112018076639A2 (en) combination chemotherapies
BR112018070302A2 (en) agents that recognize the clever-1 epitope and their uses
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2698 DE 20-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.